Core Insights - The company reported a 2% decline in CORE organic net sales and a $4 million decrease in CORE operating income for the fourth quarter, with CORE EPS at $0.76, down $0.02 year over year [1] - For the full year 2025, all-in operating income grew by 2% and EPS increased by 7% to $2.75, while on a CORE basis, operating income rose by 7% and CORE EPS increased by 14% [1][4] Financial Performance - Management presented results through two lenses: "all-in" (historical operations) and "CORE Perrigo," which excludes infant formula and announced divestitures [2] - The company reported a non-cash $1.3 billion goodwill impairment in 2025, which does not affect cash flow, but is expected to create a $0.60 EPS headwind in 2026 [6][8] - The company ended 2025 with $532 million in cash and generated fourth-quarter operating cash flow of $175 million, totaling $239 million for the full year [20] Strategic Initiatives - The CEO highlighted the "Three-S plan" aimed at simplifying, streamlining, and strengthening the business, with evidence of market share gains and over $100 million in new U.S. store-brand distribution [3][7] - A two-year program targeting annualized pre-tax savings of $80–$100 million was launched, involving a workforce reduction of approximately 7% [5][15] - The company is pursuing a sale of its dermacosmetics business and conducting a strategic review of its infant formula segment to reduce debt and improve margins [5][21] Market Trends and Outlook - The company gained market share across most U.S. OTC categories, reversing years of decline, and noted positive momentum in Europe despite a soft market environment [9] - Looking ahead, management anticipates a difficult start to 2026 for category consumption, with U.S. OTC dollar sales down 5.1% over the last 13 weeks compared to the previous year [10] - Management expects low- to mid-single-digit revenue growth in infant formula in 2026, which is anticipated to help deplete higher inventory levels [22] Future Guidance - For 2026, management guided CORE EPS to be in the range of $2.25 to $2.55, with all-in EPS expected to be between $2.00 and $2.30 [19] - The company described 2026 as a "transition year," with an unfavorable EPS impact of approximately $0.60 due to manufacturing under-absorption [14] - Management reiterated capital allocation priorities of investing in the business, reducing debt, and returning value through dividends, with expectations of achieving net leverage below 3x in the next two to three years [21]